VC Cell Therapy Inc.

  • 画像1

    Total solutions for every patient

  • 画像2

    Vision Care Group is the global leader of eye health

  • 画像3

    Eyes open to new possibilities


Total solutions for every patient


Developing and Solving Treatment Methods
for Intractable Outer Retinal Diseases

Established in December 2017, the Kobe Eye Center was founded to materialize the eye center concept proposed by our company’s representative, Masayo Takahashi. The Kobe Eye Center is a world-first endeavor that combines a regenerative medicine research facility, state-of-the-art ophthalmic medical facility, and an information care facility for social demonstration. Under the Kobe Eye Center concept, we, as the Vision Care Group, are developing regenerative medicine for untreatable retinal diseases, a new field in healthcare. Our goal is not only to commercialize regenerative medical products but also to solve healthcare system issues by making it a sustainable medical treatment.

Advancing RPE Cell Therapies

Our pioneering work in the field of regenerative medicine spans various groundbreaking developments in retinal pigment epithelium (RPE) cell research. Utilizing induced pluripotent stem cells (iPS cells), we’ve conducted clinical studies on patients with age-related macular degeneration, affirming the safety of both autologous and allogeneic RPE cell transplants. Our latest innovation, the RPE strip, offers a minimally invasive, yet precise, transplantation method that combines the advantages of both cell sheets and cell suspensions. We’re also exploring gene editing for immune-evasion to broaden the application of allogeneic RPE cell transplants. These ventures aim not only to restore lost retinal functions but also to make the therapies more accessible, cost-effective, and safer for patients.

Regeneration of Photoreceptor Cells

Our multidisciplinary team is at the forefront of regenerative medicine solutions aimed at combating photoreceptor cell dysfunction, a leading cause of blindness in aging societies like Japan. Leveraging stem cell technologies, we are developing retinal organoids as a promising approach for photoreceptor cell transplantation. In partnership with Kobe City Eye Center Hospital, we have initiated clinical research to validate the safety and efficacy of our retinal organoid-based treatments. We also employ state-of-the-art retinal differentiation techniques to generate high-quality retinal organoids. Furthermore, our latest findings underscore the functionality of transplanted photoreceptor cells, providing a viable pathway for restoring lost vision. Committed to continual improvement, we are researching next-generation strategies, including gene-editing technologies, to optimize therapeutic outcomes.

Robotic Cell Production

We have been collaborating with the Robotic Biology Institute Inc., creators of the versatile humanoid robot “Maholo”, to automate and enhance cell manufacturing processes using robotics and AI. Today, as part of the clinical research at the Kobe City Eye Center Hospital, our procedures include the use of “Maholo” in the cell cultivation stages. Here at VC Cell Therapy, we are leading the charge in implementing this robotics-assisted cell production.